QUEBEC CITY, June 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ - News; Nasdaq: AEZS - News) today announced that during a recent end of Phase 2 meeting, the U.S. Food & Drug Administration (FDA) reviewed the safety and efficacy data from an extensive Phase 2 program with cetrorelix, its lead luteinizing hormone-releasing hormone (LHRH) antagonist product candidate, for the treatment of benign prostatic hyperplasia (BPH). Accordingly, the Company plans to submit an Investigational New Drug (IND) application to the FDA within the next few months for the initiation of a Phase 3 program for cetrorelix in BPH.
